Last $3.38 USD
Change Today +0.15 / 4.64%
Volume 991.0K
CLSN On Other Exchanges
As of 1:46 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

celsion corp (CLSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/13 - $6.62
52 Week Low
04/15/14 - $2.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELSION CORP (CLSN)

celsion corp (CLSN) Related Bloomberg News

View More Bloomberg News

celsion corp (CLSN) Related Businessweek News

No Related Businessweek News Found

celsion corp (CLSN) Details

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

13 Employees
Last Reported Date: 03/13/14
Founded in 1982

celsion corp (CLSN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $434.1K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $275.2K
Chief Medical Officer and Vice President
Total Annual Compensation: $328.5K
Compensation as of Fiscal Year 2013.

celsion corp (CLSN) Key Developments

Celsion Corp. Appoints Stegman & Company as Auditor

Celsion Corp. at its Annual Meeting of Stockholders held on June 20, 2014, ratified the appointment of Stegman & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2014.

Celsion Corporation Announces Executive Appintments

The board of directors of Celsion Corporation has approved the appointment of Khursheed Anwer, Ph.D., as Executive Vice President and Chief Scientific Officer Nucleic Acid Therapy of the company. Dr. Anwer, age 55, joined the company in connection with the acquisition by CLSN Laboratories Inc. and a wholly-owned subsidiary of the company, of substantially all of the assets of Egen Inc. Dr. Anwer's appointment was effective on the closing of the acquisition, which occurred on June 20, 2014. Before joining Celsion, Dr. Anwer served as President and Chief Scientific Officer of EGEN from June 2009 to June 2014 and its Vice President of Research and Development from July 2002 to June 2009. Dr. Anwer served as a member of the board of directors of EGEN from December 2010 to June 2014. Dr. Anwer is an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, MBA STEP path. At the annual meeting, the company approved election of Dr. Augustine Chow as director.

Celsion Corp., Expression Genetics, Inc. - M&A Call

To discuss the acquisition of EGEN by Celsion Corporation


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLSN:US $3.38 USD +0.15

CLSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BSD Medical Corp $0.80 USD +0.0088
Medifocus Inc C$0.16 CAD +0.015
View Industry Companies

Industry Analysis


Industry Average

Valuation CLSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 105.8x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSION CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at